

News Segment Features CPSI's FrostBite Cancer Treatment Device

Novel technology under development by CPSI offers great potential in the battle against pancreatic cancer

May 19, 2016

OWEGO, NY – A story focusing on CPSI's novel anti-cancer device platform recently aired on FOX40 WICZ-TV Binghamton. The segment featured CPSI's FrostBite cryoablation technology which is designed to use freezing to target and destroy pancreatic cancer tumors. The FrostBite technology represents the first endoscopic ultrasound compatible trans-esophageal cryoablation device of its kind. The team at CPSI has developed the prototype catheter and conducted a series of pilot pre-clinical studies in conjunction with collaborators at John Hopkins Medical School.

Speaking about the technology, Dr. John Baust (President of CPSI) stated, "As pancreatic cancer is a highly lethal disease with limited treatment options available to patients, we are looking forward to taking the next steps in development in support of moving FrostBite closer to commercialization. While FrostBite is still in the R&D phase, the technology results look very promising and we hope to be able to move through the final development and testing necessary for FDA approval and commercialization."

Responding to questions on what it will take to get this technology into the clinic, Baust stated "Based on our promising data, we are now seeking financing to support moving the technology through final development, preclinical and clinical trials in support of gaining FDA approval for commercialization. Our financing plan focuses on private placement equity offering in a spinoff corporation focused in the GI ablation arena. Once financing is in place, we are targeting a 12-18 month window for technology finalization and submission to the FDA."

The feature story appeared on FOX40 News on Friday May 13, 2016 and can be accessed online at on their website at: <http://www.wicz.com/story/31971289/owego-company-develops-device-to-treat-pancreatic-cancer>

More information on *FrostBite* or any of CPSI's other technologies is available on CPSI's website www.cpsibiotech.com.

About CPSI Biotech - CPSI Biotech, a private, integrative bio/medtech greenhouse company, develops and designs life science research products and cryo-medical devices for applications in cancer, cardiovascular disease treatments and cell therapy bioprocessing. Ongoing R&D and business development activities continue to produce innovative technologies, devices and intellectual property for commercialization, licensing or sales in support of diverse clinical and research applications. By leveraging the innovation, flexibility and R&D strengths of CPSI in combination with the development, commercialization, manufacturing and clinical expertise of partnering organizations, rapid and efficient product development is attainable.

Disclosure Notice: The information contained in this release is as of May 16, 2016. CPSI assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. CPSI's technologies do not have regulatory clearance for commercial sale and are currently intended for "Research Use Only".

With the exception of the historical information contained in this release, this release contains materials and statements related to future business, financial performance, future events and/or developments involving CPSI which constitute forward-looking statements. The matters described herein contain forward-looking statements that involve risk and uncertainties that may individually or mutually impact the matters herein described, including but not limited to, CPSI's ability to develop and market new products, to retain and attract key employees, to obtain regulatory clearances and approvals for its products, to effectively react to other risks and uncertainties, such as fluctuation of quarterly financial results, contract and grants acquisition, reliance on third party manufacturers and suppliers, litigation or other proceedings, economic, competitive, governmental impacts, whether pending patents will be granted or defensible, validity of intellectual property and patents, the ability to license patents, the ability to commercialize developmental products, competition from existing and new products and procedures and CPSI's ability to raise the capital that is required to accomplish the foregoing.

Contacts

CPSI Biotech Contact:

John M Baust, Ph.D., President & Lead Scientist

Kristi Snyder, Ph.D., Director of Operations

Tel: 607-687-8701 Email: contact@cpsibiotech.com